Research funding provided by Huntsville philanthropist

 

Huntsville and Birmingham, Ala. – How do you glean important new information about Parkinson disease?  According to Huntsville, Ala. philanthropist John Jurenko, a good way is to put Alabama’s top biomedical investigators on the task.

“My motivation for funding the UAB-HudsonAlpha project is to utilize the outstanding capabilities of the two institutions and their expert investigators,” said Jurenko. The philanthropist recently made a collective gift of $500,000 to the two organizations toward discovering treatments that will slow, cure or even prevent the disease.

The UAB-HudsonAlpha Collaborative Project in the Genetics and Genomics of Parkinson Disease is two-fold.  Under the direction of David Standaert, M.D., Ph.D., the John and Juanelle Strain Professor and interim chair of the University of Alabama at Birmingham Department of Neurology, and Rick Myers, Ph.D., president and director of the HudsonAlpha Institute for Biotechnology, the team will use advanced technology to look at gene expression and genetic variation to provide new knowledge about the cause, effects and treatments of Parkinson disease.

Parkinson disease is a motor system disorder and results from the loss of dopamine-producing brain cells. The four major symptoms of Parkinson disease are tremor, rigidity, bradykinesia (slowness of movement) and impaired balance.  Typically, the disease affects people over the age of 50.  There are medications which can help the symptoms, but there is no treatment currently available that can stop the progression of the disease.

The project will include an unprecedented study of the effects of a neurological disease on expression of nearly all the genes in the human genome. “We now have the capability to study the effects of human disease on all 22,000 human genes,” said Myers.  In this part of the project, researchers will compare brain tissue of 100 individuals who had Parkinson disease, against 100 individuals who were free of the disease.  Ultra high throughput DNA sequencing technologies that have been developed, improved and implemented at HudsonAlpha will be employed.

The comprehensive picture will provide new insight into the nature of the disease and new treatments for its motor and non-motor impacts.
The second part of the project focuses on levodopa, the most effective single therapy for Parkinson disease.  Unfortunately, levodopa causes adverse side effects in some patients to include involuntary movement or cessation of voluntary movement.  After five years of therapy, about half of patients treated with levodopa have these side effects, referred to as dyskinesia.

Using data and samples from patients at the UAB Movement Disorders Clinic and next-generation DNA sequencing technologies, this study will identify genetic variants associated with levodopa-induced-dyskinesia. The research could have very important and immediate impact on patient therapy.

“If we can discover the genetic basis of risk for dyskinesia, we would be able to use levodopa more safely in patients who are likely to be resistant to dyskinesia, while avoiding levodopa in those at high risk for complications,” said Standaert.

All data produced during the project will be deposited in public databases for use by scientists from around the world. The project has been initiated and should be completed by the end of 2012.
“This is only the beginning,” said Jurenko. “More work and more money will be required to achieve our goal to slow or stop the progress of the disease.”
 

Contact Name:

Holly Ralston

Contact Email:

hralston@hudsonalpha.org

Contact Phone:

256.508.8954

Organization Background:

About UAB Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham is the state of Alabama’s largest employer and an internationally renowned research university and academic health center.  UAB’s neuroscience specialty patient care programs are consistently ranked among the nation’s top 50.  The UAB Parkinson’s Disease and Movement Disorder Research program is among the largest in the U.S., providing comprehensive diagnostic services, state of the art treatment and conducting a broad program of basic and clinical research. Find more information at www.uab.edu and  www.uabmedicine.org. Media contact: Bob Shepard, 205.934.8934 or bshep@uab.edu.   About HudsonAlpha The HudsonAlpha Institute for Biotechnology in Huntsville, Alabama, is the cornerstone of the Cummings Research Park Biotechnology Campus. The campus hosts a synergistic cluster of life sciences talent – science, education and business professionals – that promises collaborative innovation to turn knowledge and ideas into commercial products and services for improving human health and strengthening Alabama’s progressively diverse economy. The non-profit institute is housed in a state-of-the-art, 270,000 square-ft. facility strategically located in the nation’s second largest research park. HudsonAlpha has a three-fold mission of genomic research, economic development and educational outreach.

File Attachment:

Research funding provided by Huntsville philanthropist

HUNTSVILLE and BIRMINGHAM, Ala. – How do you glean important new information about Parkinson disease?  According to Huntsville, Ala. philanthropist John Jurenko, a good way is to put Alabama’s top biomedical investigators on the task.

“My motivation for funding the UAB-HudsonAlpha project is to utilize the outstanding capabilities of the two institutions and their expert investigators,” said Jurenko. The philanthropist recently made a collective gift of $500,000 to the two organizations toward discovering treatments that will slow, cure or even prevent the disease.

The UAB-HudsonAlpha Collaborative Project in the Genetics and Genomics of Parkinson Disease is two-fold.  Under the direction of David Standaert, M.D., Ph.D., the John and Juanelle Strain Professor and interim chair of the University of Alabama at Birmingham Department of Neurology, and Rick Myers, Ph.D., president and director of the HudsonAlpha Institute for Biotechnology, the team will use advanced technology to look at gene expression and genetic variation to provide new knowledge about the cause, effects and treatments of Parkinson disease.

Parkinson disease is a motor system disorder and results from the loss of dopamine-producing brain cells. The four major symptoms of Parkinson disease are tremor, rigidity, bradykinesia (slowness of movement) and impaired balance.  Typically, the disease affects people over the age of 50.  There are medications which can help the symptoms, but there is no treatment currently available that can stop the progression of the disease.

The project will include an unprecedented study of the effects of a neurological disease on expression of nearly all the genes in the human genome. “We now have the capability to study the effects of human disease on all 22,000 human genes,” said Myers.  In this part of the project, researchers will compare brain tissue of 100 individuals who had Parkinson disease, against 100 individuals who were free of the disease.  Ultra high throughput DNA sequencing technologies that have been developed, improved and implemented at HudsonAlpha will be employed.

The comprehensive picture will provide new insight into the nature of the disease and new treatments for its motor and non-motor impacts.
The second part of the project focuses on levodopa, the most effective single therapy for Parkinson disease.  Unfortunately, levodopa causes adverse side effects in some patients to include involuntary movement or cessation of voluntary movement.  After five years of therapy, about half of patients treated with levodopa have these side effects, referred to as dyskinesia.

Using data and samples from patients at the UAB Movement Disorders Clinic and next-generation DNA sequencing technologies, this study will identify genetic variants associated with levodopa-induced-dyskinesia. The research could have very important and immediate impact on patient therapy.

“If we can discover the genetic basis of risk for dyskinesia, we would be able to use levodopa more safely in patients who are likely to be resistant to dyskinesia, while avoiding levodopa in those at high risk for complications,” said Standaert.

All data produced during the project will be deposited in public databases for use by scientists from around the world. The project has been initiated and should be completed by the end of 2012.

“This is only the beginning,” said Jurenko. “More work and more money will be required to achieve our goal to slow or stop the progress of the disease.”

Media Contact: Beth Pugh
bpugh@hudsonalpha.org
256-327-0443

About HudsonAlphaHudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to innovating in the field of genomic technology and sciences across a spectrum of biological problems. Its mission is three-fold: sparking scientific discoveries that can impact human health and well-being; fostering biotech entrepreneurship; and encouraging the creation of a genomics-literate workforce and society. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. Designed to be a hothouse of biotech economic development, HudsonAlpha’s state-of-the-art facilities co-locate scientific researchers with entrepreneurs and educators. The relationships formed on the HudsonAlpha campus allow serendipity to yield results in medicine and agriculture. Since opening in 2008, HudsonAlpha, under the leadership of Dr. Richard M. Myers, a key collaborator on the Human Genome Project, has built a name for itself in genetics and genomics research and biotech education, and boasts 26 biotech companies on campus.

About UAB: Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham is the state of Alabama’s largest employer and an internationally renowned research university and academic health center.  UAB’s neuroscience specialty patient care programs are consistently ranked among the nation’s top 50.  The UAB Parkinson’s Disease and Movement Disorder Research program is among the largest in the U.S., providing comprehensive diagnostic services, state of the art treatment and conducting a broad program of basic and clinical research. Find more information at www.uab.edu and  www.uabmedicine.org. Media contact: Bob Shepard, 205.934.8934 or bshep@uab.edu.